New research explores how antimicrobial exposure affects Parkinson’s disease risk

Antibiotic exposure shows potential protective effects against Parkinson’s, while antifungal use is linked to increased risk, indicating microbiome involvement.

Y-mAbs Therapeutics sees highest filings and grants during June in Q2 2024

Y-mAbs Therapeutics has been focused on protecting inventions in Australia(AU) with three publications in Q2 2024 The Australia(AU) Patent Office dominates the patent filings with

July 21, 2024

First Treatment for Demodex Blepharitis Wins FDA Approval

The FDA approved lotilaner ophthalmic solution 0.25% (Xdemvy) as the first specific treatment for Demodex blepharitis. Lotilaner (formerly TP-03) is an ectoparasiticide that targets Demodex

July 27, 2023

Tirofiban a Better Option for Ischemic Stroke When Lytics and Thrombectomy Aren’t?

PHOENIX — For acute ischemic stroke patients without thrombolytic or thrombectomy options, tirofiban was better than aspirin alone, the TREND trial showed. In non-cardioembolic stroke,

February 10, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.